Balanced news tone
News Sentiment
PCRX sentiment intelligence
Pacira BioSciences, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
86/100 classification confidence.
directly relevant articles
high-authority source matches
+0.4% over one week, +10.8% over four weeks, trend active, and near fair-value range.
PCRX6079820 Bond Coupon Profile — Rate & Payments
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Price to earnings forward of Pacira Biosciences, Inc. – FWB:82P
This page displays the "Price to earnings forward" metric for Pacira Biosciences, Inc. (FWB:82P) on the Frankfurt Stock Exchange. The current value for this financial indicator is presented, along with the option to view change and change percentage over a period.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Jun 2026 00:10
- Source
- TradingView
Pacira BioSciences (NASDAQ: PCRX) SVP Finance sells shares under 10b5-1 plan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 07:00
- Source
- Stock Titan
Three major proxy firms side with Pacira in boardroom showdown
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jun 2026 07:00
- Source
- Stock Titan
Pacira Biosciences Inc (NASDAQ:PCRX) Emerges as a Deep Value Opportunity with Strong Financial Health
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- ChartMill
Pacira cites 31% stock jump, $726M sales in fight with DOMA for board seats
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 May 2026 07:00
- Source
- Stock Titan
Considering Pacira Biosciences Inc (PCRX) Stock After Q1 Report? Check the Details
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 May 2026 07:00
- Source
- Market source
PACIRA BIOSCIENCES INC (NASDAQ:PCRX): A Value Stock Candidate with Margin of Safety
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 05 May 2026 07:00
- Source
- ChartMill
Pacira BioSciences Inc. (PCRX) Stock Rises on Q4 2025 Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 30 Apr 2026 07:00
- Source
- Quiver Quantitative
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Mar 2026 07:00
- Source
- PR Newswire
Pacira Pharmaceuticals, Inc. (PCRX) Stock Price Today & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jan 2026 20:12
- Source
- Gotrade
Revenues Working Against Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Share Price Following 28% Dive
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jan 2026 08:00
- Source
- simplywall.st
How Investors May Respond To Pacira BioSciences (PCRX) Activist Pressure Amid Buybacks And Rising EXPAREL Revenue
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 09 Jan 2026 08:00
- Source
- Market source
DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Nov 2025 08:00
- Source
- PR Newswire
Pacira BioSciences (PCRX) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jun 2015 03:15
- Source
- MarketBeat